Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01808534 · OUTCOME

Treatment Related Adverse Events Grade 3 or Higher

Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors · Source last updated 2015-07-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Up to 2 years

What was measured

Number of unique patients who had a treatment related (possible, probable or definite) adverse event that was graded 3 or greater according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03.

Analysis population: All patients who enrolled and received treatment.

Groups in this outcome

Treatment (Palifosfamide)

Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Palifosfamide)5

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Palifosfamide)1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      5
    units
    Participants
description
Number of unique patients who had a treatment related (possible, probable or definite) adverse event that was graded 3 or greater according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
groups
  1. description
    Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Palifosfamide)
param Type
NUMBER
population Description
All patients who enrolled and received treatment.
reporting Status
POSTED
time Frame
Up to 2 years
title
Treatment Related Adverse Events Grade 3 or Higher
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice